

# 2015 Strategies in the US Hospital Tumor Marker Testing Market

<https://marketpublishers.com/r/2069ECB5BA3EN.html>

Date: February 2015

Pages: 567

Price: US\$ 5,200.00 (Single User License)

ID: 2069ECB5BA3EN

## Abstracts

This new report from VPGMarketResearch contains 567 pages, 50 tables, and presents a comprehensive analysis of the US hospital tumor market testing market, including:

Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.

Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.

Test volume and sales forecasts for 40 tumor markers performed in US hospitals.

Current instrumentation technologies and feature comparison of leading analyzers.

Sales and market shares of leading suppliers.

Emerging diagnostic technologies and their potential market applications.

Product development opportunities.

Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

Business opportunities and strategic recommendations for suppliers.

Contains 567 pages and 50 tables

## Contents

### Introduction

### Worldwide Market and Technology Overview

#### A. Cancer Statistics and Etiology

1. BREAST CANCER
2. LUNG CANCER
3. COLON AND RECTUM CANCER
4. PROSTATE CANCER
5. STOMACH CANCER
6. LEUKEMIA
7. LYMPHOMA
8. ORAL CANCER
9. SKIN CANCER
10. UTERINE CANCER
11. OVARIAN CANCER
12. BLADDER CANCER

#### B. Major Current And Emerging Cancer Diagnostic Tests

1. INTRODUCTION
2. TUMOR MARKER CLASSIFICATION
3. ACTH
4. ALPHA-FETOPROTEIN (AFP)
5. BETA-2 MICROGLOBULIN
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. CALCITONIN
10. CARCINOEMBRYONIC ANTIGEN (CEA)
11. ESTROGEN AND PROGESTERONE RECEPTORS
12. FERRITIN
13. GASTRIN
14. HUMAN CHORIONIC GONADOTROPIN (HCG)
15. INSULIN
16. NSE
17. OCCULT BLOOD
18. PAP SMEAR/HPV
19. PROSTATIC ACID PHOSPHATASE (PAP)

- 20. PROSTATE-SPECIFIC ANTIGEN (PSA)
- 21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
- 22. T AND B LYMPHOCYTES
- 23. TDT
- 24. THYROGLOBULIN
- 25. TISSUE POLYPEPTIDE ANTIGEN (TPA)
- 26. BIOCHEMICAL TUMOR MARKERS
  - ADA
  - B-Protein
  - PNP
  - 5'-Nucleotidase
- 27. ONCOGENES
  - Abl/abl-bcr
  - AIB1
  - BCL-2
  - BRCA1
  - CD44
  - C-fos
  - C-myb
  - C-myc
  - CYP-17
  - Erb-B
  - HPC1
  - N-myc
  - P40
  - P51
  - P53
  - PIK3CA
  - PTI-1
  - Ras
  - Reg
  - Sis
  - Src
- 28. POLYPEPTIDE GROWTH FACTORS
  - Basic Fibroblast Growth Factor
  - Beta-TGF
  - Cachectin (TNT)
  - Calmodulin
  - ECFR

Nerve Growth Factor (NGF)  
Epidermal Growth Factor (EGF)  
Ornithine Decarboxylase  
Transferrin  
Transforming Growth Factor-Alpha  
29. ECTOPIC HORMONES  
30. COLONY STIMULATING FACTORS  
31. LYMPHOKINES  
Alpha-Interferon  
B Cell Growth Factors  
B Cell Growth Factor (BCGF)  
Gamma-Interferon  
Interleukin-1 (IL-1)  
Macrophage Activating Factor  
32. IMMUNOHISTOCHEMICAL STAINS  
33. EMERGING TUMOR MARKERS  
N-Acetylglucosamine  
Actin  
Alpha-Actin  
Antineuronal Antibodies  
7B2  
B72.3  
Bax  
BCD-F9  
BLCA-4  
Blood Group Antigens A,B,H  
CA  
CA 72-4/TAG-72  
CA  
CA-242  
CA-549  
CAM  
CAR-3  
Cathepsin-D  
Chromogranin A and B  
Cluster 1 Antigen  
Cluster-5/5A Antigen  
CTA  
CU18

DR-70  
DU-PAN-2  
Endometrial Bleeding Associated Factor  
Endostatin  
Epithelial Membrane Antigen  
Feulgen Hydrolysis  
Fibronectin  
FSH  
(1->3)-L-fucosyltransferase  
Gastrin-Releasing Peptide (GRP)  
GDCFP-15  
Glucagon  
Glycoamines  
H23  
Her-2  
Human Carcinoma Antigen  
HPA  
HSP27  
Intermediate Filaments  
Cytokeratins/CK18/Cyfra 21-1  
Desmin  
Gliofibrillary Acid Protein  
Neurofilaments  
Vimentin  
KA  
Kinases  
KP16D3  
LAI  
Leukocyte Common Antigen  
Lewis Antigens  
Lysophosphatidic Acid (LPA)  
Ma 695/Ma  
MABDF3  
MAG  
ME1  
Minactivin  
MN/CA9  
MSA  
Mucin Cancer Antigen (MCA)

Multiple Tumor Suppressor  
Myosin  
NEA-130  
NMP22  
OA-519  
Opioid Peptides  
P-glycoprotein  
Pancreatic Oncofetal Antigen (POA)  
Placental Lactogen  
PR92  
Proliferative Index, Ki-67  
Px  
RB Inactivation/Deletion  
Ret  
SCCL  
Selectin  
Sialic Acid  
Sialyl SSEA-1/SLX  
SN10  
Somatostatin  
TA-90  
TABA  
Tachykinin  
TAG  
TPS  
Troponin  
Tubulin  
VCAM  
VEGF  
Villan  
C. Instrumentation Review And Market Needs  
1. ABBOTT AXSYM  
2. ABBOTT ARCHITECT C4000  
3. ABBOTT ARCHITECT I200 SERIES  
4. ABBOTT ARCHITECT CI820 SYSTEM  
5. BECKMAN COULTER UNICEL SERIES  
6. BECKMAN COULTER ACCESS  
7. BINDING SITE ESP600  
8. BIOMERIEUX MINI VIDAS

9. CAROLINA CHEMISTRIES BIOLIS 24I
10. DIASORIN LIAISON
11. HORIBA ABX PENTRA
12. INVERNESS DS2
13. J&J VITROS ECI/ECIQ
14. J&J VITROS 3600
15. J&J VITROS 5600
16. OLYMPUS AU5400
17. OLYMPUS AU3000I
18. OLYMPUS AU2700
19. ROCHE MODULAR ANALYTICS
20. ROCHE COBAS INTEGRA
21. ROCHE COBAS INTEGRA 40 PLUS
22. ROCHE ELECSYS
23. ROCHE COBAS C311
24. SIEMENS ADVIA CENTAUR
25. SIEMENS DIMENSION
26. SIEMENS DIMENSION RXL MAX
27. SIEMENS DIMENSION VISTA
28. SIEMENS IMMULITE
29. SIEMENS STRATUS
30. TOSOH AIA-SERIES
31. VITAL DIAGNOSTICS ATAC 8000
32. VITAL DIAGNOSTICS ENVOY

#### D. Current and Emerging Technologies

##### 1. MONOCLONAL AND POLYCLONAL ANTIBODIES

##### 2. IMMUNOASSAYS

- a. Technological Principle
- b. Radioimmunoassay (RIA)
- c. Enzyme Immunoassays (EIA)

#### Overview

#### ELISA

#### Immunofiltration

#### Particle-Membrane Capture Immunoassay

#### Enzyme Amplification

- d. Fluorescent Immunoassays
- e. Luminescence

#### Chemiluminescence

#### Bioluminescence

- f. Latex Agglutination
- g. Immunoprecipitation
- H. Affinity Chromatography
  - e. Liposome Flow-Injection Immunoassay
- 3. MOLECULAR DIAGNOSTICS
  - a. Technology Overview
  - b. Amplification Methods
- PCR
- DAP-PCR
- Immuno-PCR
- QC-PCR
- CAR
- DNA
- HPA
- LCR
- NASBA
- QBR
- SDA
- 3 SR, and others
- 4. CHROMOSOME ANALYSIS
  - a. Chronic Myelogenous Leukemia (CML)
  - b. Acute Myeloid Leukemia (AML)
  - c. Acute Lymphoblastic Leukemia (ALL)
  - d. Malignant Lymphomas Lymphoid Malignancies
  - e. Chronic Lymphocytic Leukemia (CLL)
  - f. Solid Cancers
  - g. Chromosomal Translocation and Oncogenes
- 5. ARTIFICIAL INTELLIGENCE
- 6. FLOW CYTOMETRY
- 7. TWO DIMENSIONAL GEL ELECTROPHORESIS (2-DGE)
- 8. BIOSENSORS
- 9. COMPETING/COMPLEMENTING TECHNOLOGIES
  - a. CT
  - b. MRI
  - c. NMR
  - d. PET
  - e. Photonics Spectroscopy
- E. Personal Testing

## **U.S.A.**

### **A. Executive Summary**

### **B. Business Environment**

#### **1. HEALTH CARE EXPENDITURES**

#### **2. COST CONSCIOUSNESS**

#### **3. INDUSTRY CONSOLIDATION**

#### **4. MANAGED CARE**

#### **5. HOSPITALS**

#### **6. ADMISSIONS**

#### **7. LENGTH OF STAY**

#### **8. INDUSTRY DIVERSIFICATION**

#### **9. PHYSICIAN DEMOGRAPHICS**

#### **10. POPULATION AGING**

##### **a. Chronic Illness**

##### **b. Disease Incidence**

##### **c. Susceptibility to Iatrogenesis**

##### **d. Multiple Illness Cases**

#### **11. LABORATORY REGULATIONS**

### **C. Market Structure**

#### **1. CENTRALIZED TESTING**

##### **a. Hospitals**

##### **b. Commercial/Private Laboratories**

#### **2. POT/DECENTRALIZED TESTING**

##### **a. Physician Offices/Group Practices**

##### **b. Cancer Clinics**

##### **c. Point-Of-Care Testing**

##### **d. Other Decentralized Testing Locations**

### **D. Market Size, Growth and Major Suppliers Sales, Instrument Placements and Market Shares**

## **MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES**

### **A. Reagent Kits and Test Systems/Panels**

### **B. Instrumentation**

### **C. Computers, Software and Automation**

### **D. Auxiliary Products**

## **DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS**

## **ALTERNATIVE MARKET PENETRATION STRATEGIES**

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
- 1. MARKETING APPROACHES
- 2. PRODUCT COMPLEXITY
- 3. CUSTOMER PREFERENCE
- 4. ESTABLISHED SUPPLIERS
- 5. EMERGING SUPPLIERS
- 6. MAJOR TYPES OF DISTRIBUTORS
- 7. MARKET SEGMENTATION FACTOR

## **POTENTIAL MARKET ENTRY BARRIERS AND RISKS**

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

## **COMPETITIVE PROFILES**

Abbott  
AdnaGen  
Applied Gene Technologies  
Arca  
Beckman Coulter/Danaher  
Becton Dickinson  
Biomedical Diagnostics  
bioMerieux  
Bio-Rad  
Cepheid  
Correlogic Systems  
Dako  
Decode  
Diadexus  
Diagnocure

Diasorin  
Eiken Chemical  
Enterix  
Enzo Biochem  
Epigenomics  
Exact Sciences  
Fujirebio  
Gen-Probe  
Guided Therapeutics  
Hologic  
Ipsogen  
Kreatech  
Kyowa Medex  
Life Technologies  
Mackay Life Sciences  
Myriad Genetics  
Nanogen Elitech  
OncoLab  
Otho-Clinical Diagnostics  
Panacea Pharmaceuticals  
Polartech  
Polymedco  
PreMD  
Qiagen  
Radiant Pharmaceuticals  
Roche  
Scienion  
Sequenom  
Siemens Healthcare  
Takara Bio  
Targeted Diagnostics & Therapeutics  
Tosoh  
Veridex  
Wako Pure Chemicals  
Wallac/PE  
Zila

## List Of Tables

### LIST OF TABLES

Tumor Marker Classification

Major Companies Developing or Marketing ACTH Tests

Major Companies Developing or Marketing AFP Tests

Major Companies Developing or Marketing Beta-2 Microglobulin Tests

Major Companies Developing or Marketing CA 15-3/27.29 Tests

Major Companies Developing or Marketing CA 19-9 Tests

Major Companies Developing or Marketing CA 125 Tests

Major Companies Developing or Marketing Calcitonin Tests

Major Companies Developing or Marketing CEA Tests

Major Companies Developing or Marketing Estrogen Receptor Tests

Major Companies Developing or Marketing Progesterone Receptor Tests

Major Companies Developing or Marketing Ferritin Tests

Major Companies Developing or Marketing Gastrin Tests

Major Companies Developing or Marketing HCG Tests

Major Companies Developing or Marketing Insulin Tests

Major Companies Developing or Marketing NSE Tests

Major Companies Developing or Marketing Occult Blood Tests

Major Companies Developing or Marketing PAP Smear/HPV Tests

Major Companies Developing or Marketing PAP Tests

Major Companies Developing or Marketing PSA Tests

Major Companies Developing or Marketing Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications In Cancer Diagnosis

Oncogenes Potential Applications In Cancer Diagnosis

Major Companies Developing or Marketing Oncogene Tests Growth Factors Potential Applications In Cancer Diagnosis

Colony Stimulating Factors Potential Applications in Cancer Diagnosis

Lymphokines Potential Applications In Cancer Diagnosis

Immunohistochemical Stains Potential Applications in Cancer Diagnosis

Executive Summary Table: U.S., Hospital Cancer Diagnostic Test Volume and Sales Forecast

U.S., Estimated New Cancer Cases and Deaths

U.S., Estimated Cancer Death Rates Per 100,00 Population

U.S., Laboratories Performing Cancer Diagnostic Tests

U.S., Hospital Laboratories Performing Cancer Diagnostics Tests by Bed Size

U.S., Hospital Laboratories Major Cancer Diagnostic Test Volume Forecast by Test

U.S., Total Cancer Diagnostics Sales By Major Supplier  
U.S., ACTH Testing Market Diagnostics Sales by Major Supplier  
U.S., AFP Testing Market Diagnostics Sales by Major Supplier  
U.S., Beta-2 Microglobulin Testing Market Diagnostics Sales by Major Supplier  
U.S., CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier  
U.S., CA 19-9 Testing Market Diagnostics Sales by Major Supplier  
U.S., CA 125 Testing Market Diagnostics Sales by Major Supplier  
U.S., CEA Testing Market Diagnostics Sales by Major Supplier  
U.S., Ferritin Testing Market Diagnostics Sales by Major Supplier  
U.S., HCG Testing Market Diagnostics Sales by Major Supplier  
U.S., Insulin Testing Market Diagnostics Sales by Major Supplier  
U.S., Parathyroid Hormone Testing Market Diagnostics Sales by Major Supplier  
U.S., PAP Testing Market Diagnostics Sales by Major Supplier  
U.S., Progesterone Receptor Testing Market Diagnostics Sales by Major Supplier  
U.S., PSA Testing Market Diagnostics Sales by Major Supplier

## I would like to order

Product name: 2015 Strategies in the US Hospital Tumor Marker Testing Market

Product link: <https://marketpublishers.com/r/2069ECB5BA3EN.html>

Price: US\$ 5,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2069ECB5BA3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970